My next article titled "Immunotherapy Investing 101" will feature my top ten companies and their I/O asset and which are best positioned for success in 2016 and beyond.
I will hit submit the day Peregrine announces fully enrolled sunrise.
This article if approved will have a much broader audience and of course my shining star is Bavituximab.
Market Data 
Markets 
AI
